10 Things For Pfizer's New CEO To Worry About
Albert Bourla will face opportunities and potential pitfalls.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.